- Home
- INSW vs NVAX Comparison
INSW vs NVAX Comparison
Compare INSW & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSW
- NVAX
- Stock Information
- Founded
- INSW 1999
- NVAX 1987
- Country
- INSW United States
- NVAX United States
- Employees
- INSW N/A
- NVAX N/A
- Industry
- INSW Semiconductors
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INSW Technology
- NVAX Health Care
- Exchange
- INSW Nasdaq
- NVAX Nasdaq
- Market Cap
- INSW 1.7B
- NVAX 1.3B
- IPO Year
- INSW N/A
- NVAX 1995
- Fundamental
- Price
- INSW $37.73
- NVAX $5.98
- Analyst Decision
- INSW Strong Buy
- NVAX Buy
- Analyst Count
- INSW 3
- NVAX 6
- Target Price
- INSW $56.67
- NVAX $17.50
- AVG Volume (30 Days)
- INSW 744.2K
- NVAX 8.5M
- Earning Date
- INSW 05-08-2025
- NVAX 05-08-2025
- Dividend Yield
- INSW 10.88%
- NVAX N/A
- EPS Growth
- INSW N/A
- NVAX N/A
- EPS
- INSW 6.47
- NVAX 2.97
- Revenue
- INSW $860,606,000.00
- NVAX $1,254,962,000.00
- Revenue This Year
- INSW N/A
- NVAX N/A
- Revenue Next Year
- INSW $1.20
- NVAX N/A
- P/E Ratio
- INSW $5.82
- NVAX $2.01
- Revenue Growth
- INSW N/A
- NVAX 25.92
- 52 Week Low
- INSW $27.20
- NVAX $4.43
- 52 Week High
- INSW $65.94
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- INSW 65.98
- NVAX 43.78
- Support Level
- INSW $35.75
- NVAX $5.82
- Resistance Level
- INSW $37.23
- NVAX $7.50
- Average True Range (ATR)
- INSW 1.17
- NVAX 0.56
- MACD
- INSW 0.50
- NVAX 0.00
- Stochastic Oscillator
- INSW 96.67
- NVAX 8.71
About INSW International Seaways Inc.
International Seaways Inc owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products. The company's vessel operations are organized into two segments: Crude Tankers and Product Carriers. The fleet consists of ULCC, VLCC, Suezmax, Aframax, and Panamax crude tankers, as well as LR1, LR2, and MR product carriers.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.